rs1436844070
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PM2PP3_ModeratePP5_Very_Strong
The NM_001232.4(CASQ2):āc.164A>Gā(p.Tyr55Cys) variant causes a missense change. The variant allele was found at a frequency of 0.0000297 in 1,613,986 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (ā ā ). Synonymous variant affecting the same amino acid position (i.e. Y55Y) has been classified as Likely benign.
Frequency
Consequence
NM_001232.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 12 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CASQ2 | ENST00000261448.6 | c.164A>G | p.Tyr55Cys | missense_variant | 1/11 | 1 | NM_001232.4 | ENSP00000261448.5 | ||
CASQ2 | ENST00000488931.2 | n.-113A>G | 5_prime_UTR_premature_start_codon_gain_variant | 2/13 | 3 | ENSP00000518226.1 | ||||
CASQ2 | ENST00000488931.2 | n.-113A>G | non_coding_transcript_exon_variant | 2/13 | 3 | ENSP00000518226.1 | ||||
CASQ2 | ENST00000488931.2 | n.-113A>G | 5_prime_UTR_variant | 2/13 | 3 | ENSP00000518226.1 |
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 152160Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.00000796 AC: 2AN: 251356Hom.: 0 AF XY: 0.00000736 AC XY: 1AN XY: 135844
GnomAD4 exome AF: 0.0000308 AC: 45AN: 1461826Hom.: 0 Cov.: 33 AF XY: 0.0000303 AC XY: 22AN XY: 727222
GnomAD4 genome AF: 0.0000197 AC: 3AN: 152160Hom.: 0 Cov.: 32 AF XY: 0.0000404 AC XY: 3AN XY: 74332
ClinVar
Submissions by phenotype
Catecholaminergic polymorphic ventricular tachycardia 2 Pathogenic:2
Likely pathogenic, criteria provided, single submitter | clinical testing | Center for Human Genetics, University of Leuven | Feb 09, 2017 | ACMG score likely pathogenic - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Apr 11, 2023 | - - |
Catecholaminergic polymorphic ventricular tachycardia 1 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 11, 2023 | This sequence change replaces tyrosine, which is neutral and polar, with cysteine, which is neutral and slightly polar, at codon 55 of the CASQ2 protein (p.Tyr55Cys). This variant is present in population databases (no rsID available, gnomAD 0.003%). This missense change has been observed in individual(s) with catecholaminergic polymorphic ventricular tachycardia (CPVT) (PMID: 18684293, 21618644). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 427946). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt CASQ2 protein function with a positive predictive value of 80%. Experimental studies are conflicting or provide insufficient evidence to determine the effect of this variant on CASQ2 function (PMID: 32693635). For these reasons, this variant has been classified as Pathogenic. - |
Cardiovascular phenotype Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Sep 27, 2024 | The p.Y55C variant (also known as c.164A>G), located in coding exon 1 of the CASQ2 gene, results from an A to G substitution at nucleotide position 164. The tyrosine at codon 55 is replaced by cysteine, an amino acid with highly dissimilar properties. This variant has been identified in conjunction with other CASQ2 variant(s) in individual(s) with features consistent with catecholaminergic polymorphic ventricular tachycardia (CPVT) (de la Fuente S et al. Pacing Clin Electrophysiol, 2008 Jul;31:916-9; Roux-Buisson N et al. Hum Mutat, 2011 Sep;32:995-9; Robyns T et al. Eur J Hum Genet, 2017 Dec;25:1313-1323; van Lint FHM et al. Neth Heart J, 2019 Jun;27:304-309; Ng K et al. Circulation, 2020 Sep;142:932-947; Bergeman AT et al. Neth Heart J, 2023 Nov;31:444-451). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This amino acid position is not well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Based on the majority of available evidence to date, this variant is likely to be pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at